at 533

AT-533 is a potent inhibitor of Hsp90 and HSV. AT-533 blocks the HIF-1α/VEGF/VEGFR-2 signaling pathway, leading to suppress tumor growth and angiogenesis. AT-533 also inhibits the activation of the downstream pathways, including Erk1/2, FAK, Akt/mTOR/p70S6K,. AT-533 inhibits the cell migration, invasion, and the tube formation of human umbilical vein endothelial cells (HUVECs).

VU533 (Nape-Pld activator) is a NAPE-PLD activator with an EC50 value of 0.30 µM.VU533 enhances NAPE-PLD activity and increases macrophage cytosolic burial.VU533 may be used in diseases associated with cardiometabolism.

pp60 c-src (521-533) (phosphorylated) acetate is a regulator of focal adhesion formation and cell spreading. pp60 c-src (521-533) (phosphorylated) acetate also regulates cell motility and is a key component in the signaling pathway triggered by the motogenic hyaluronan receptor RHAMM.

KRA-533 is an effective KRAS agonist that targets the GTP/GDP binding pocket within the KRAS protein, inhibiting GTP cleavage. This leads to accumulation of the active GTP-KRAS form, promoting apoptosis and autophagic death in cancer cells.

NB-533 is a macrocyclic peptidic BACE-1 inhibitor.

ORIC-533 is a selective CD73 inhibitor that is orally active and competes with AMP. It revitalizes the proliferation and activation of immunosuppressed CD8+ T cells and induces notable lysis and cell death in multiple myeloma cells within the bone marrow microenvironment [1].

Peptide corresponding to the pp60c-src carboxy terminal regulatory domain; phosphorylated at Tyr527. Binds to pp60c-src and pp60v-src at the SH2 domain, suppressing their tyrosine kinase activity and transforming potential.